Clesitamig

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A trispecific T-cell engager antibody directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3), the T-cell costimulatory receptor CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, clesitamig targets and binds to DLL3 expressed on tumor cells, CD3 expressed on T-cells, and CD137 expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. The binding to DLL3 and CD3 activates and redirects cytotoxic T-lymphocytes (CTLs) to DLL3-expressing tumor cells, which results in the CTL-mediated cell death of DLL3-expressing tumor cells. The binding to CD137 enhances CD137-mediated signaling, induces CTL proliferation and cytokine production, and further promotes a CTL-mediated anti-tumor immune response as well as induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of regulatory T-cells (Tregs). CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. DLL3, a Notch pathway protein, is overexpressed on a variety of cancer cell types. It plays a key role in embryonic development and in tumor initiation and proliferation.

**Synonyms:** - ALPS 12 - ALPS-12 - ALPS12 - Anti-DLL3/CD3/CD137 Trispecific Antibody ALPS12 - Anti-DLL3/CD3/CD137 Trispecific Antibody RG6524 - Anti-DLL3/CD3/CD137 Trispecific Antibody RO7616789 - CLESITAMIG - RG 6524 - RG-6524 - RG6524 - RO 7616789 - RO-7616789 - RO7616789